Rubius therapeutics, inc. (RUBY)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Operating expenses:
Research and development

36,186

30,500

33,530

27,518

20,871

16,539

14,363

11,361

9,506

6,126

4,821

General and administrative

12,664

14,928

14,952

13,767

13,535

12,583

13,191

9,023

5,097

5,849

4,212

Total operating expenses

48,850

45,428

48,482

41,285

34,406

29,122

27,554

20,384

14,603

11,975

9,033

Loss from operations

-48,850

-45,428

-48,482

-41,285

-34,406

-29,122

-27,554

-20,384

-14,603

-11,975

-9,033

Other income (expense):
Interest income

1,049

-

-

-

2,308

-

-

-

-

-

-

Interest expense

985

633

835

539

583

205

87

89

83

90

72

Change in fair value of preferred stock warrant liability

-

-

-

-

-

0

426

1,718

43

59

493

Other income (expense), net

300

-

-

-

100

-

-

-

-

-

-

Interest income and other income, net

-

-

2,302

2,434

-

-

1,705

952

318

205

44

Total other income (expense), net

364

956

1,467

1,895

1,825

1,939

1,192

-855

192

56

-521

Net loss

-48,486

-44,472

-47,015

-39,390

-32,581

-27,183

-26,362

-21,239

-14,411

-11,919

-9,554

Accretion of Series A redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

280

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-11,919

-9,834

Net loss per share, basic and diluted

-0.60

-0.57

-0.59

-0.50

-0.42

2.30

-0.42

-2.43

-1.72

-1.48

-1.25

Weighted average common shares outstanding, basic and diluted

80,271

79,699

79,115

78,396

77,544

77,748

62,311

8,727

8,355

8,078

7,866

Comprehensive loss:
Net loss

-48,486

-44,472

-47,015

-39,390

-32,581

-27,183

-26,362

-21,239

-14,411

-11,919

-9,554

Other comprehensive income (loss):
Unrealized gains (losses) on investments, net of tax of $0

456

-91

-124

209

110

-10

8

18

-45

-

-

Comprehensive loss

-48,030

-44,563

-47,139

-39,181

-32,471

-27,193

-26,354

-21,221

-14,456

-11,919

-9,554